ESCHER-GROUP
9.10.2018 07:12:12 CEST | Business Wire | Press release
Post-Expo 2018, Booth #B1.360 – Escher Group , the company transforming the postal and courier market with their innovative customer engagement platform, today announced that Nick Manolis has been named chief executive officer (CEO) of Escher, and that he has also been appointed to the company’s board of directors. For more than two decades, postal operators and couriers have relied on Escher to improve their customer experience at all points of engagement, accelerate service delivery and help them to transform their business to a more efficient variable cost model in a budget-constrained world. Escher has emerged as the worldwide market leader in customer engagement solutions for postal point-of-service (POS), and Manolis will be responsible for leading the company’s continued global expansion.
“Nick is a proven executive in leading high-performing, customer-centric technology companies,” said Matthew Peacock, founding partner at Hanover and Escher board member. “That talent combined with his success in innovating global retail platform solutions makes him a perfect fit to lead Escher as the company looks to expand its reach globally into new countries, and postal and courier markets.”
Outdated IT infrastructure and antiquated operating models no longer work for postal operators and couriers who need to manage the growth of parcels and adapt to today’s digitally savvy customers who want to be engaged on their own terms. Forward-looking postal executives are investing in customer engagement platforms to provide the best customer experience, increase revenues and move to a variable cost model.
With its unique and purpose-built customer engagement platform, Escher enables postal operators to shift to modern and profitable customer engagement strategies that embrace today’s digitally disruptive world. With new and deeper points of engagement – including third-party locations, kiosks, expanded pick-up drop-off (PUDO) locations and mobile point of sale – Escher makes it easier for postal customers to do business. Escher drives efficiency by automating and streamlining business processes and easily operationalizing new points of engagement. New services can be rolled out in days and third-party services can be implemented overnight.
With 25 unique post-centric technology patents, Escher has been able to deploy more than 350 thousand customer engagement points globally, which has resulted in more than two billion transactions processed annually. Escher has transformed how 35 postal operators around the globe profitably interact with their customers.
“Postal operators and couriers worldwide rely on Escher as they make the shift to a modern and profitable customer engagement strategy and embrace today’s digitally disruptive world. Our platform allows them to rapidly deliver new services and capabilities, while also providing a superior customer experience. With Escher, postal executives can do more with the resources with which they are entrusted,” said Nick Manolis. “I am honored to work with the exceptional team at Escher and the posts we serve globally.”
Manolis has spent the last ten years at TrueCommerce, a global provider of retail trading partner connectivity and integration solutions, as president and CEO. Under Manolis’ leadership, TrueCommerce provided a global trading platform that connected 12,000 suppliers with nearly 92,000 retailers worldwide.
Meet Manolis and the Escher team, and learn more about Escher’s customer engagement platform at Post-Expo booth #B1.360.
About Escher
Escher is transforming postal operators and couriers worldwide, enabling them to engage today’s digitally savvy customers across all points of engagement. With Escher’s unique, purpose-built customer engagement platform, posts can drive superior customer experience, with greater speed and better economics. Learn more: www.eschergroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005847/en/
Contact:
Media Contact 280blue, Inc. Amanda McKinney amanda@280blue.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom